Cancer Diagnostics Market
Cancer Diagnostics to take a turn for the better, thanks to incorporation of AI and other Smart Technologies
Cancer Diagnostics Market by Test Type, Indication, End Use, Region & Forecast 2022 to 2032
Cancer Diagnostics Market Snapshot (2022 to 2032)
[285 Pages Report] The global cancer diagnostics market is projected to expand steadily at a CAGR 7.1% value, during the forecast period 2022 to 2032. In the year 2022, the market size is projected to expand and gain a global market valuation of US$ 191 Billion. Considering this increasing growth and demand in the global market, the cancer diagnostics market is expected to reach US$ 379 Billion by 2032.
Cancer is among the top causes of mortality worldwide, and its incidence is increasing at an alarming rate. As a result, healthcare experts are concentrating on the development of efficient treatment and diagnosis solutions in order to reduce the incidence level. Early detection improves treatment regimen success rates. As a consequence, healthcare institutions and industry companies are pushing routine exams through different awareness efforts.
|
Data Points |
Key Statistics |
|
Global Growth Rate (2022 to 2032) |
7.1% CAGR |
|
Cancer Diagnostics Market Value 2022 |
US$ 191 Billion |
|
Cancer Diagnostics Market Projected Value (2032) |
US$ 379 Billion |
Increases in the prevalence and incidence of different forms of cancer, such as lung cancer and breast cancer, will boost the cancer diagnostics market over the projected period. Furthermore, a spike in technical improvements supporting the improved imaging of dangerous cells, innovations in equipment to detect the kind of cancer, and an increase in the accuracy of the result would assist the cancer diagnostics market in gaining momentum throughout the projection period. Increased government activities and other private groups to raise awareness about early cancer identification and prevention are expected to drive market expansion in the future years.
Furthermore, increased diagnostics laboratory infrastructure in developed nations is projected to drive the market in the coming years. During the predicted period, there will be a significant increase in emphasis on health and safety laws, as well as a boom in popularity of yoga and other health-related practices. However, the high cost of diagnostic imaging systems and the development of diverse diagnostic techniques for distinct cancer mutations may stymie market expansion.
Let us know your requirement to get
100% FREE customization
2017 to 2021 Cancer Diagnostics Market Demand Analysis vs. Forecast 2022 to 2032
According to market research and competitive intelligence provider Future Market Insights- the market for cancer diagnostics reflected a value of 5.9% during the historical period, 2017 to 2021. National lockdown, government controls, and a spike in infection rates across countries all had a major financial impact on neurological clinics and hospitals. Several clinics and hospitals have seen a decrease in patient visits as a result of COVID-19, thereby minimizing client engagement.
Furthermore, many cancer diagnoses have been pushed back as a result of the COVID-19 dilemma. There was a global shortage of medical treatment for disorders other than COVID-19, which has had a detrimental influence on the cancer diagnostics business. Also, the restricted availability of healthcare personnel throughout the world is another aspect that has a negative impact on the cancer diagnostics industry.
However, post the pandemic, the complication in various people have increased. People suffering from even stage 1 cancer faced complications as the effects of the virus affected the immune system gravely. This paced up the demand for various drugs and also made the companies to expand the product portfolio to provide enhanced immunity to the patients. As a result the demand is expected to go over 7% CAGR during the forecast period.
Prominent Growth Drivers Influencing Cancer Diagnostics Market
Increasing use of AI to boost the demand of Cancer Diagnostics
The usage of AI in cancer detection is also predicted to boost market growth. AI technologies have been created by scientists to help screening tests for several types of cancer, particularly breast cancer. For more than 20 years, AI-based computer algorithms have been used to assist clinicians in interpreting mammograms, but research in this field is rapidly expanding.
For example, Freenome, a United States based AI genomics startup, is focusing on creating blood tests that utilize Artificial Intelegence to detect the body's early-warning indications of cancer. In October 2018, the business revealed preliminary findings from research and development for applying machine learning to identify colorectal cancer in its early stages.
The NCI's Center for Cancer Research, for example, built an AI model that might help radiologists identify possibly aggressive prostate cancer on a relatively new type of prostate MRI scan called multiparametric MRI. As a result, such achievements are projected to move the company forward in the worldwide market.
Establishment of Private Diagnostic Centers to aid Cancer Diagnostics Market Growth
The amount of private diagnostic centers is expanding across the world as the demand for diagnostic imaging operations rises and the load on public hospitals grows due to the restricted number of imaging techniques available. In January 2021, FUJIFILM Corporation established NURA, a cancer screening medical screening center in Bangalore, India. FUJIFILM DKH LLP (FUJIFILM DKH) and Dr. Kutty's Healthcare run this medical screening center (DKH). FUJIFILM DKH LLP (FUJIFILM DKH) is a FUJIFILM and Dr. Kutty's Healthcare (DKH) joint venture that operates hospitals and screening facilities throughout India and the Middle East.
Various centers are also working on liquid biopsy and animal cancer therapies at the same time. The advancement of biopsy platforms for companion animal malignancies is likely to provide profitable growth prospects for global cancer diagnostics market participants.
For example, Zomedica Pharmaceuticals Corp., a veterinary diagnostic and pharmaceutical business, stated in January 2020 that it has completed the development and manufacture of their reference lab cancer liquid biopsy platform for canine malignancies. These advanced developments in this field are expected to accelerate the global cancer diagnostics market during the forecast period.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat could Possibly Hinder Cancer Diagnostics Market Demand?
Poor Reimbursement Policies and Higher Cost will restrict Market Growth
Inadequate reimbursement regulations are predicted to stymie market expansion. In recent years, there have been several developments in radiology in terms of imaging equipment. However, most medical insurance companies do not cover procedures that use computer-aided detection (CAD). As a consequence, individuals choose traditional diagnostic methods such as biopsies, pathology tests, or conventional imaging methods such as mammography and MRI treatments.
Furthermore, the high cost of cancer detection software is projected to stifle market expansion. Computer-aided Detection (CAD) software comes with a one-year license, which hospitals must renew each year. Furthermore, some insurance companies are opting out of CAD procedure reimbursement since it is judged excessive and not recommended by senior radiologists. Such hindrances will affect the global market during the forecast period.
Category-wise Insights
Which Test Type is forecast to gain the Maximum Market Share?
The Imaging Segment will dominate the segment during the Forecast Period
With a 58% market share in 2021, the imaging category led the market and is likely to retain its dominance throughout the forecast period. Modalities used in imaging like computed Tomography (CT) scans and Magnetic Resonance Imaging (MRI) are rapid, non-invasive, and painless diagnostic methods.
Imaging aids in cancer staging, as do prognostic and therapy system monitoring of metabolic and functional information. Due to these advantages, the use of imaging modalities in cancer screening programmes has significantly grown. Globally, the use of sophisticated imaging tests including such as multiphoton microscopy and magnetic resonance imaging is increasing.
The various imaging modalities, in conjunction with other genetic and laboratory testing, are employed as supporting tests in detecting a range of cancer forms, aiding in the selection of a suitable treatment strategy. These factors are expected to propel the imaging segment at an 8.0% CAGR throughout the forecast period.
Which Indication Segment will gain the larger share during The Forecast Period?
Breast Cancer Indication to gain significance during the forecast period
In 2021, the breast cancer sector held the major portion of the cancer diagnostics market, accounting for Mammography has become the most frequent and widely used screening technique 34.0%. for breast tumors.
Women between the ages of 50 and 74 are at a greater risk of getting breast cancer, according to the United States Preventive Services Task Force (USPSTF). As a result, the USPSTF advises that women over the age of 40 have mammography done every two years.
Furthermore, several organizations, such as the National Breast Cancer Foundation, Inc., are launching campaigns to raise awareness about breast cancer, the benefits of early detection, and available treatment choices. Increased public awareness, along with campaigns supporting routine mammography, is driving rising demand for scanning solutions in breast cancer detection.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Region-wise Analysis
What is the outlook of the North American Cancer Diagnostics Market?
Presence of various medical firms will boost the market demand for cancer diagnostics
In terms of market share and revenue, the North American market is predicted to be the most lucrative market for cancer diagnostics during the forecast period, 2022 and 2032. In 2021, the regional cancer diagnostics market boomed with a revenue share of 45%
One of the primary factors propelling the diagnostics industry in the region is the presence of various biotechnology and medical device firms. North America is likely to maintain its lead during the projection period due to factors such as increased spending for R&D initiatives and widespread use of new technology.
Furthermore, the region's high concentration of important players, growing FDA approvals, strategic partnerships, and substantial expenditure in research & development activities are projected to enhance the market. Merck & Co. Inc, for example, entered into a formal agreement in November 2020 to purchase Velosbio Inc., a privately owned clinical-stage biopharmaceutical firm dedicated to developing first-in-class cancer medicines targeting the receptor tyrosine kinase-like orphan receptor 1. (ROR1). Such advancements will make the demand stronger in this region during the forecast period.
How is the growth of the cancer diagnostics market emerging in the Asia Pacific?
Increasing cancer incidences and low treatment rates will boost the demand in this region
During the projection period, Asia Pacific is expected to grow at a CAGR of 6.9%. In the coming years, the Asia Pacific area is expected to be one of the emerging economies for cancer diagnostics.
Due to the existence of a big patient pool, the availability of experienced technicians at a reduced cost, and a clear regulatory environment encouraging quicker product approvals, Asia Pacific is likely to display the strongest growth in the near future. Furthermore, the burgeoning medical tourism business in countries like China, India, and Malaysia is likely to increase demand for cancer diagnosis and treatment screening.
East Asia's growth rate is predicted to accelerate. According to the World Health Organization, approximately 4.7 million new cancer cases will be diagnosed in China by 2025. Obesity and hormone exposure-related malignancies, such as breast cancer in women, and "lifestyle change-related diseases," such as prostate cancer in men, are on the rise in China, resulting in increased use of cancer diagnostics. These incidents will boost the regional growth for cancer diagnostics.
What will be the outlook of the European cancer diagnostics market during the forecast period?
Desirable policies and growing diagnostic centers will accelerate the demand
The European cancer diagnostics market is predicted to increase significantly throughout the forecast period, with a CAGR of 5.2% during 2022-2032.
Desirable healthcare policies, along with high average per capita healthcare costs, have produced a favorable climate in the United Kingdom for the adoption of modern cancer diagnostic technology such as imaging. In addition, the existence of major players promotes expansion in the United Kingdom. These firms' strategies include new releases and growth initiatives, which will continue to help overall expansion in Europe.
Start-up Scenario
- Race Oncology is an ASX-listed precise oncology firm that is developing Zantrene®, a Phase 2/3 cancer medication. Zantrene® is a powerful fatso/fat mass and obesity linked (FTO) protein inhibitor. Overexpression of FTO has been identified as a genetic driver of a variety of malignancies. Race is investigating the potential of Zantrene® as a novel treatment for melanoma and clear cell renal cell carcinoma, two malignancies that frequently over-express FTO. In groundbreaking preclinical research, Race revealed that Zantrene® protects against anthracycline-induced heart damage while also functioning in combination with anthracyclines to boost their capacity to target breast cancer. Race is assessing this discovery.
- Carer, which was founded in 2018, aims to improve the quality of life of every cancer patient in the convenience of their own home. It attempts to give patients with the best degree of support and therapy both during and after treatment to help recovery. Their therapy has a significant benefit in that it can be tailored to each patient's diagnosis, prior health difficulties, and chosen lifestyle, making it more feasible in the long run. This is accomplished through their three-pronged approach, which includes a dietary protocol, a movement and meditation protocol, and a mental well-being protocol which educates and motivates patients and caregivers to make life-changing adjustments for more successful healing.
Competitive Landscape
The adoption of novel goods and their significant R&D efforts to offer developments in the same have helped major companies operating in the sector maintain a strong position in the worldwide market. The market's competition is projected to heat up in the near future, as numerous businesses are focusing their efforts on research and the introduction of novel diagnostic procedures through product line expansions and acquisitions and mergers.
- Gland Pharma has launched the cancer treatment medicine Bortezomib for Injection in the United States in 2022. The drug business stated in a statement that it has released the medicine in the United States market through a partner who has acquired permission from the United States Food and Drug Administration (USFDA). The business claims that its medicine is medically similar to Velcade for Injection from Takeda Pharmaceuticals. Bortezomib for Intravenous is used to treat cancers such as myeloma and mantle cell lymphoma.
- Bristol-Myers Squibb K.K. announced in 2022 that the Japanese Ministry of Health, Labour, and Welfare had approved Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the the treatment of adult patients with refractory or relapsed (R/R) multiple myeloma who had received a minimum of three prior therapies. In Japan, Abecma was the first CAR T cell therapy licensed for treating R/R multiple myeloma in 2021. In Japan, Abecma is the first CAR T cell therapy licensed for treating R/R multiple myeloma in 2021. Bristol Myers Squibb is currently the only firm in Japan with two authorized CAR T cell therapies: the CD19-directed Breyanzi, which was approved in March 2021, and the BCMA-directed Abecma.
Report Scope
|
Report Attribute |
Details |
|
Growth Rate |
CAGR of 7.1% from 2022 to 2032 |
|
Market Value for 2022 |
US$ 191 Billion |
|
Market Value for 2032 |
US$ 379 Billion |
|
Base Year for Estimation |
2021 |
|
Historical Data |
2017 to 2021 |
|
Forecast Period |
2022 to 2032 |
|
Quantitative Units |
US$ Billion for Value |
|
Report Coverage |
Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Report Customization & Pricing |
Available upon Request |
Key Segments Covered In the Cancer Diagnostics Market Report
Cancer Diagnostics Market by Test Type:
- Tumor Biomarkers Tests
- PSA Tests
- CTC Tests
- AFP Tests
- CA Tests
- HER2 Tests
- BRCA Tests
- ALK Tests
- CEA Tests
- EGFR Mutation Tests
- KRAS Mutation Tests
- Others
- Imaging
- Ultrasound
- Mammography
- MRI Scan
- PET Scan
- CT Scan
- SPECT & Others
- Biopsy
- Needle Biopsy
- Endoscopic Biopsy
- Bone Marrow Biopsy
- Others
- Liquid Biopsy
- Immunohistochemistry
- In Situ Hybridization
Cancer Diagnostics Market by Indication:
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Melanoma
- Blood Cancer
- Prostate Cancer
- Ovarian Cancer
- Stomach Cancer
- Liver Cancer
- Others
Cancer Diagnostics Market by End User:
- Hospital Associated Labs
- Independent Diagnostic Laboratories
- Diagnostic Imaging Centers
- Cancer Research Institutes
- Others
Cancer Diagnostics Market by Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa (MEA)
Frequently Asked Questions
From 2017-2021, the cancer diagnostics market grew at a CAGR of 5.9%
The global cancer diagnostics market is expected to grow with a 7.1% CAGR during 2022-2032.
As of 2032, the cancer diagnostics market is expected to reach US$ 379 Billion
In 2021, the imaging category by test type occupied a 58% market share and is expected to dominate the global market in 2022 too.
By indication, the breast segment held a global market share of 38% in 2021.
The North American cancer diagnostics market was projected to gain a global market share of 45% in 2021.
Asia Pacific is expected to grow steadily with a CAGR of 6.9% during 2022-2032.
During the forecast period, the European market for cancer diagnostics will exhibit a 5.2% CAGR.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Market Dynamics
2.4. Inclusions and Exclusions
3. Market Background
3.1. Macro-Economic Factors
3.1.1. Global GDP Growth Outlook
3.1.2. Global Healthcare Expenditure Outlook
3.1.3. Growth of Healthcare Sector in Emerging Nations
3.2. Forecast Factors - Relevance & Impact
3.2.1. Global Increase in Healthcare Expenditure
3.2.2. Rising Prevalence of Cancer
3.2.3. Changing Regulatory Dynamics
3.2.4. Cost Impact
3.2.5. Regulatory Scenario
3.3. Market Dynamics
3.3.1. Drivers
3.3.2. Restraints
3.3.3. Opportunity Analysis
4. Market Context
4.1. Key Industry Developments
4.2. Disease Epidemiology
4.3. Regulatory and Reimbursement Scenario
4.4. Strategic Promotional Strategies by Manufacturer
5. COVID19 Crisis Impact Analysis
5.1.1. Current perspectives on the Coronavirus outbreak
5.1.2. Current GDP Projection and Probable Impact
5.1.3. Current Economic Projection as compared to 2008 Economic analysis
5.1.4. COVID19 and Impact Analysis
5.2. Market Revenue Impact Analysis
5.2.1. Historical (pre-COVID), Current (during-COVID), Future (post-COVID)
5.2.1.1. By Test Type
5.2.1.2. By Indication
5.2.1.3. By End User
5.2.1.4. By Region
5.2.2. 2020 Market Scenario
5.3. Impact on Trends Analysis
5.4. Recovery Scenario – Short term, Midterm and Long Term Impact
6. Global Market Value (US$ Mn) Analysis 2017-2021 and Forecast, 2021–2031
6.1. Historical Market Value (US$ Mn) Analysis, 2017-2021
6.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032
6.2.1. Y-o-Y Growth Trend Analysis
6.2.2. Absolute $ Opportunity Analysis
7. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Test Type
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Mn) Analysis By Test Type, 2017-2021
7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Test Type, 2022-2032
7.3.1. Tumor Biomarkers Tests
7.3.1.1. PSA Tests
7.3.1.2. CTC Tests
7.3.1.3. AFP Tests
7.3.1.4. CA Tests
7.3.1.5. HER2 Tests
7.3.1.6. BRCA Tests
7.3.1.7. ALK Tests
7.3.1.8. CEA Tests
7.3.1.9. EGFR Mutation Tests
7.3.1.10. KRAS Mutation Tests
7.3.1.11. Others
7.3.2. Imaging
7.3.2.1. Ultrasound
7.3.2.2. Mammography
7.3.2.3. MRI Scan
7.3.2.4. PET Scan
7.3.2.5. CT Scan
7.3.2.6. SPECT & Others
7.3.3. Biopsy
7.3.3.1. Needle Biopsy
7.3.3.2. Endoscopic Biopsy
7.3.3.3. Bone Marrow Biopsy
7.3.3.4. Others
7.3.4. Liquid Biopsy
7.3.5. Immunohistochemistry
7.3.6. In Situ Hybridization
7.4. Market Attractiveness Analysis By Test Type
8. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Indication
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Indication, 2017-2021
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2022-2032
8.3.1. Breast Cancer
8.3.2. Lung Cancer
8.3.3. Colorectal Cancer
8.3.4. Melanoma
8.3.5. Blood Cancer
8.3.6. Prostate Cancer
8.3.7. Ovarian Cancer
8.3.8. Stomach Cancer
8.3.9. Liver Cancer
8.3.10. Others
8.4. Market Attractiveness Analysis By Indication
9. Global Market Analysis 2017-2021 and Forecast 2022-2032, By End User
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By End User, 2017-2021
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2022-2032
9.3.1. Hospital Associated Labs
9.3.2. Independent Diagnostic Laboratories
9.3.3. Diagnostic Imaging Centers
9.3.4. Cancer Research Institutes
9.3.5. Others
9.4. Market Attractiveness Analysis By End User
10. Global Market Analysis 2017-2021 and Forecast 2022-2032, by Region
10.1. Introduction
10.2. Historical Market Size (US$ Mn) Analysis By Region, 2017-2021
10.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2022-2032
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. East Asia
10.3.5. South Asia
10.3.6. Oceania
10.3.7. Middle East and Africa (MEA)
10.4. Market Attractiveness Analysis By Region
11. North America Market Analysis 2017-2021 and Forecast 2022-2032
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021
11.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2022-2032
11.3.1. By Country
11.3.1.1. U.S.
11.3.1.2. Canada
11.3.2. By Test Type
11.3.3. By Indication
11.3.4. By End User
11.4. Market Attractiveness Analysis
11.5. Key Market Participants - Intensity Mapping
11.6. Drivers and Restraints - Impact Analysis
12. Latin America Market Analysis 2017-2021 and Forecast 2022-2032
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021
12.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2022-2032
12.3.1. By Country
12.3.1.1. Brazil
12.3.1.2. Mexico
12.3.1.3. Argentina
12.3.1.4. Rest of Latin America
12.3.2. By Test Type
12.3.3. By Indication
12.3.4. By End User
12.4. Market Attractiveness Analysis
12.5. Key Market Participants - Intensity Mapping
12.6. Drivers and Restraints - Impact Analysis
13. Europe Market Analysis 2017-2021 and Forecast 2022-2032
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021
13.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2022-2032
13.3.1. By Country
13.3.1.1. Germany
13.3.1.2. Italy
13.3.1.3. France
13.3.1.4. U.K.
13.3.1.5. Spain
13.3.1.6. BENELUX
13.3.1.7. Russia
13.3.1.8. Rest of Europe
13.3.2. By Test Type
13.3.3. By Indication
13.3.4. By End User
13.4. Market Attractiveness Analysis
13.5. Key Market Participants - Intensity Mapping
13.6. Drivers and Restraints - Impact Analysis
14. South Asia Market Analysis 2017-2021 and Forecast 2022-2032
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021
14.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2022-2032
14.3.1. By Country
14.3.1.1. India
14.3.1.2. Thailand
14.3.1.3. Indonesia
14.3.1.4. Malaysia
14.3.1.5. Rest of South Asia
14.3.2. By Test Type
14.3.3. By Indication
14.3.4. By End User
14.4. Market Attractiveness Analysis
14.5. Key Market Participants - Intensity Mapping
14.6. Drivers and Restraints - Impact Analysis
15. East Asia Market Analysis 2017-2021 and Forecast 2022-2032
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021
15.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2022-2032
15.3.1. By Country
15.3.1.1. China
15.3.1.2. Japan
15.3.1.3. South Korea
15.3.2. By Test Type
15.3.3. By Indication
15.3.4. By End User
15.4. Market Attractiveness Analysis
15.5. Key Market Participants - Intensity Mapping
15.6. Drivers and Restraints - Impact Analysis
16. Oceania Market Analysis 2017-2021 and Forecast 2022-2032
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021
16.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2022-2032
16.3.1. By Country
16.3.1.1. Australia
16.3.1.2. New Zealand
16.3.2. By Test Type
16.3.3. By Indication
16.3.4. By End User
16.4. Market Attractiveness Analysis
16.5. Key Market Participants - Intensity Mapping
16.6. Drivers and Restraints - Impact Analysis
17. Middle East and Africa Market Analysis 2017-2021 and Forecast 2022-2032
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021
17.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2022-2032
17.3.1. By Country
17.3.1.1. GCC Countries
17.3.1.2. South Africa
17.3.1.3. Rest of Middle East and Africa
17.3.2. By Test Type
17.3.3. By Indication
17.3.4. By End User
17.4. Market Attractiveness Analysis
17.5. Key Market Participants - Intensity Mapping
17.6. Drivers and Restraints - Impact Analysis
18. Key and Emerging Countries Market Analysis 2017-2021 and Forecast 2022-2032
18.1. Introduction
18.1.1. Market Value Proportion Analysis, By Key Countries
18.1.2. Global Vs. Country Growth Comparison
18.2. U.S. Market Analysis
18.2.1. By Test Type
18.2.2. By Indication
18.2.3. By End User
18.3. Canada Market Analysis
18.3.1. By Test Type
18.3.2. By Indication
18.3.3. By End User
18.4. Mexico Market Analysis
18.4.1. By Test Type
18.4.2. By Indication
18.4.3. By End User
18.5. Brazil Market Analysis
18.5.1. By Test Type
18.5.2. By Application
18.5.3. By Indication
18.5.4. By End User
18.6. U.K. Market Analysis
18.6.1. By Test Type
18.6.2. By Indication
18.6.3. By End User
18.7. Germany Market Analysis
18.7.1. By Test Type
18.7.2. By Indication
18.7.3. By End User
18.8. France Market Analysis
18.8.1. By Test Type
18.8.2. By Indication
18.8.3. By End User
18.9. Italy Market Analysis
18.9.1. By Test Type
18.9.2. By Indication
18.9.3. By End User
18.10. France Market Analysis
18.10.1. By Test Type
18.10.2. By Indication
18.10.3. By End User
18.11. Spain Market Analysis
18.11.1. By Test Type
18.11.2. By Indication
18.11.3. By End User
18.12. Russia Market Analysis
18.12.1. By Test Type
18.12.2. By Indication
18.12.3. By End User
18.13. Poland Market Analysis
18.13.1. By Test Type
18.13.2. By Indication
18.13.3. By End User
18.14. China Market Analysis
18.14.1. By Test Type
18.14.2. By Indication
18.14.3. By End User
18.15. Japan Market Analysis
18.15.1. By Test Type
18.15.2. By Indication
18.15.3. By End User
18.16. South Korea Market Analysis
18.16.1. By Test Type
18.16.2. By Indication
18.16.3. By End User
18.17. India Market Analysis
18.17.1. By Test Type
18.17.2. By Indication
18.17.3. By End User
18.18. Thailand Market Analysis
18.18.1. By Test Type
18.18.2. By Indication
18.18.3. By End User
18.19. Indonesia Market Analysis
18.19.1. By Test Type
18.19.2. By Indication
18.19.3. By End User
18.20. Malaysia Market Analysis
18.20.1. By Test Type
18.20.2. By Indication
18.20.3. By End User
18.21. Australia Market Analysis
18.21.1. By Test Type
18.21.2. By Indication
18.21.3. By End User
18.22. New Zealand Market Analysis
18.22.1. By Test Type
18.22.2. By Indication
18.22.3. By End User
18.23. GCC Countries Market Analysis
18.23.1. By Test Type
18.23.2. By Indication
18.23.3. By End User
18.24. Turkey Market Analysis
18.24.1. By Test Type
18.24.2. By Indication
18.24.3. By End User
18.25. South Africa Market Analysis
18.25.1. By Test Type
18.25.2. By Indication
18.25.3. By End User
19. Market Structure Analysis
19.1. Market Analysis by Tier of Companies
19.2. Market Share Analysis of Top Players
19.3. Market Concentration
19.4. Competition Benchmarking
19.5. Market Presence Analysis
19.5.1. Regional Footprint by Players
19.5.2. Product Foot print by Players
19.5.3. Channel Foot Print by Players
20. Competition Analysis
20.1. Competition Dashboard
20.2. Competition Deep Dive (Tentative List)
20.2.1. Abbott Laboratories
20.2.1.1. Overview
20.2.1.2. Product Portfolio
20.2.1.3. Profitability by Market Segments (Product/Channel/Region)
20.2.1.4. Sales Footprint
20.2.1.5. Strategy Overview
20.2.1.5.1. Marketing Strategy
20.2.1.5.2. Product Strategy
20.2.1.5.3. Channel Strategy
20.2.2. Roche Holding AG
20.2.2.1. Overview
20.2.2.2. Product Portfolio
20.2.2.3. Profitability by Market Segments (Product/Channel/Region)
20.2.2.4. Sales Footprint
20.2.2.5. Strategy Overview
20.2.2.5.1. Marketing Strategy
20.2.2.5.2. Product Strategy
20.2.2.5.3. Channel Strategy
20.2.3. Thermo Fisher Scientific Inc.
20.2.3.1. Overview
20.2.3.2. Product Portfolio
20.2.3.3. Profitability by Market Segments (Product/Channel/Region)
20.2.3.4. Sales Footprint
20.2.3.5. Strategy Overview
20.2.3.5.1. Marketing Strategy
20.2.3.5.2. Product Strategy
20.2.3.5.3. Channel Strategy
20.2.4. Siemens AG
20.2.4.1. Overview
20.2.4.2. Product Portfolio
20.2.4.3. Profitability by Market Segments (Product/Channel/Region)
20.2.4.4. Sales Footprint
20.2.4.5. Strategy Overview
20.2.4.5.1. Marketing Strategy
20.2.4.5.2. Product Strategy
20.2.4.5.3. Channel Strategy
20.2.5. Bio Rad Laboratories Inc
20.2.5.1. Overview
20.2.5.2. Product Portfolio
20.2.5.3. Profitability by Market Segments (Product/Channel/Region)
20.2.5.4. Sales Footprint
20.2.5.5. Strategy Overview
20.2.5.5.1. Marketing Strategy
20.2.5.5.2. Product Strategy
20.2.5.5.3. Channel Strategy
20.2.6. GE Healthcare
20.2.6.1. Overview
20.2.6.2. Product Portfolio
20.2.6.3. Profitability by Market Segments (Product/Channel/Region)
20.2.6.4. Sales Footprint
20.2.6.5. Strategy Overview
20.2.6.5.1. Marketing Strategy
20.2.6.5.2. Product Strategy
20.2.6.5.3. Channel Strategy
20.2.7. Illumina, Inc
20.2.7.1. Overview
20.2.7.2. Product Portfolio
20.2.7.3. Profitability by Market Segments (Product/Channel/Region)
20.2.7.4. Sales Footprint
20.2.7.5. Strategy Overview
20.2.7.5.1. Marketing Strategy
20.2.7.5.2. Product Strategy
20.2.7.5.3. Channel Strategy
20.2.8. Koninklijke Philips N.V.
20.2.8.1. Overview
20.2.8.2. Product Portfolio
20.2.8.3. Profitability by Market Segments (Product/Channel/Region)
20.2.8.4. Sales Footprint
20.2.8.5. Strategy Overview
20.2.8.5.1. Marketing Strategy
20.2.8.5.2. Product Strategy
20.2.8.5.3. Channel Strategy
20.2.9. Toshiba Medical Systems Corporation
20.2.9.1. Overview
20.2.9.2. Product Portfolio
20.2.9.3. Profitability by Market Segments (Product/Channel/Region)
20.2.9.4. Sales Footprint
20.2.9.5. Strategy Overview
20.2.9.5.1. Marketing Strategy
20.2.9.5.2. Product Strategy
20.2.9.5.3. Channel Strategy
20.2.10. Agilent Technologies, Inc.
20.2.10.1. Overview
20.2.10.2. Product Portfolio
20.2.10.3. Profitability by Market Segments (Product/Channel/Region)
20.2.10.4. Sales Footprint
20.2.10.5. Strategy Overview
20.2.10.5.1. Marketing Strategy
20.2.10.5.2. Product Strategy
20.2.10.5.3. Channel Strategy
21. Assumptions and Acronyms Used
22. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Test Type
Table 02: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication
Table 03: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User
Table 04: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Region
Table 05: North America Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2021–2031, By Country
Table 06: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Test Type
Table 07: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication
Table 08: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User
Table 09: Latin America Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2021–2031, By Country
Table 10: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Test Type
Table 11: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication
Table 12: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User
Table 13: Europe Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2021–2031, By Country
Table 14: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Test Type
Table 15: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication
Table 16: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User
Table 17: South Asia Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2021–2031, By Country
Table 18: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Test Type
Table 19: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication
Table 20: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User
Table 21: East Asia Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2021–2031, By Country
Table 22: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Test Type
Table 23: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication
Table 24: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User
Table 25: Oceania Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2021–2031, By Country
Table 26: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Test Type
Table 27: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication
Table 28: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User
Table 29: MEA Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2021–2031, By Country
Table 30: MEA Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Test Type
Table 31: MEA Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication
Table 32: MEA Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 01: Global Market Value Analysis (US$ Mn), 2017-2021
Figure 02: Global Market Value Forecast (US$ Mn), 2022-2032
Figure 03: Global Market Absolute $ Opportunity, 2022-2032
Figure 04: Global Market Share Analysis (%),By Test Type, 2022-2032
Figure 05: Global Market Y-o-Y Analysis (%), By Test Type, 2022-2032
Figure 06: Global Market Attractiveness Analysis By Test Type, 2022-2032
Figure 07: Global Market Share Analysis (%), By Indication, 2022-2032
Figure 08: Global Market Y-o-Y Analysis (%), By Indication, 2022-2032
Figure 09: Global Market Attractiveness Analysis By Indication, 2022-2032
Figure 10: Global Market Share Analysis (%), By End User, 2022-2032
Figure 11: Global Market Y-o-Y Analysis (%), By End User, 2022-2032
Figure 12: Global Market Attractiveness Analysis by End User, 2022-2032
Figure 13: Global Market Share Analysis (%), By Region, 2022-2032
Figure 14: Global Market Y-o-Y Analysis (%), By Region, 2022-2032
Figure 15: Global Market Attractiveness Analysis by Region, 2022-2032
Figure 16: North America Market Value Share, By Test Type, 2021 (E)
Figure 17: North America Market Value Share, By Indication, 2021 (E)
Figure 18: North America Market Value Share, By End User, 2021 (E)
Figure 19: North America Market Value Share, By Country, 2021 (E)
Figure 20: North America Market Value Analysis (US$ Mn), 2017-2021
Figure 21: North America Market Value Forecast (US$ Mn), 2022-2032
Figure 22: North America Market Attractiveness Analysis By Test Type, 2022-2032
Figure 23: North America Market Attractiveness Analysis By Indication, 2022-2032
Figure 24: North America Market Attractiveness Analysis by End User, 2022-2032
Figure 25: North America Market Attractiveness Analysis by Country, 2022-2032
Figure 26: Latin America Market Value Share, By Test Type, 2021 (E)
Figure 27: Latin America Market Value Share, By Indication, 2021 (E)
Figure 28: Latin America Market Value Share, By End User, 2021 (E)
Figure 29: Latin America Market Value Share, By Country, 2021 (E)
Figure 30: Latin America Market Value Analysis (US$ Mn), 2017-2021
Figure 31: Latin America Market Value Forecast (US$ Mn), 2022-2032
Figure 32: Latin America Market Attractiveness Analysis By Test Type, 2022-2032
Figure 33: Latin America Market Attractiveness Analysis By Indication, 2022-2032
Figure 34: Latin America Market Attractiveness Analysis by End User, 2022-2032
Figure 35: Latin America Market Attractiveness Analysis by Country, 2022-2032
Figure 36: Europe Market Value Share, By Test Type, 2021 (E)
Figure 37: Europe Market Value Share, By Indication, 2021 (E)
Figure 38: Europe Market Value Share, By End User, 2021 (E)
Figure 39: Europe Market Value Share, By Country, 2021 (E)
Figure 40: Europe Market Value Analysis (US$ Mn), 2017-2021
Figure 41: Europe Market Value Forecast (US$ Mn), 2022-2032
Figure 42: Europe Market Attractiveness Analysis By Test Type , 2022-2032
Figure 43: Europe Market Attractiveness Analysis By Indication, 2022-2032
Figure 44: Europe Market Attractiveness Analysis by End User, 2022-2032
Figure 45: Europe Market Attractiveness Analysis by Country, 2022-2032
Figure 46: South Asia Market Value Share, By Test Type, 2021 (E)
Figure 47: South Asia Market Value Share, By Indication, 2021 (E)
Figure 48: South Asia Market Value Share, By End User, 2021 (E)
Figure 49: South Asia Market Value Share, By Country, 2021 (E)
Figure 50: South Asia Market Value Analysis (US$ Mn), 2017-2021
Figure 51: South Asia Market Value Forecast (US$ Mn), 2022-2032
Figure 52: South Asia Market Attractiveness Analysis By Test Type, 2022-2032
Figure 53: South Asia Market Attractiveness Analysis By Indication, 2022-2032
Figure 54: South Asia Market Attractiveness Analysis by End User, 2022-2032
Figure 55: South Asia Market Attractiveness Analysis by Country, 2022-2032
Figure 56: East Asia Market Value Share, By Test Type, 2021 (E)
Figure 57: East Asia Market Value Share, By Indication, 2021 (E)
Figure 58: East Asia Market Value Share, By End User, 2021 (E)
Figure 59: East Asia Market Value Share, By Country, 2021 (E)
Figure 60: East Asia Market Value Analysis (US$ Mn), 2017-2021
Figure 61: East Asia Market Value Forecast (US$ Mn), 2022-2032
Figure 62: East Asia Market Attractiveness Analysis By Test Type, 2022-2032
Figure 63: East Asia Market Attractiveness Analysis By Indication, 2022-2032
Figure 64: East Asia Market Attractiveness Analysis by End User, 2022-2032
Figure 65: East Asia Market Attractiveness Analysis by Country, 2022-2032
Figure 66: Oceania Market Value Share, By Test Type, 2021 (E)
Figure 67: Oceania Market Value Share, By Indication, 2021 (E)
Figure 68: Oceania Market Value Share, By End User, 2021 (E)
Figure 69: Oceania Market Value Share, By Country, 2021 (E)
Figure 70: Oceania Market Value Analysis (US$ Mn), 2017-2021
Figure 71: Oceania Market Value Forecast (US$ Mn), 2022-2032
Figure 72: Oceania Market Attractiveness Analysis By Test Type, 2022-2032
Figure 73: Oceania Market Attractiveness Analysis By Indication, 2022-2032
Figure 74: Oceania Market Attractiveness Analysis by End User, 2022-2032
Figure 75: Oceania Market Attractiveness Analysis by Country, 2022-2032
Figure 76: MEA Market Value Share, By Test Type, 2021 (E)
Figure 77: MEA Market Value Share, By Indication, 2021 (E)
Figure 78: MEA Market Value Share, By End User, 2021 (E)
Figure 79: MEA Market Value Share, By Country, 2021 (E)
Figure 80: MEA Market Value Analysis (US$ Mn), 2017-2021
Figure 81: MEA Market Value Forecast (US$ Mn), 2022-2032
Figure 82: MEA Market Attractiveness Analysis By Test Type, 2022-2032
Figure 83: MEA Market Attractiveness Analysis By Indication, 2022-2032
Figure 84: MEA Market Attractiveness Analysis by End User, 2022-2032
Figure 85: MEA Market Attractiveness Analysis by Country, 2022-2032
Figure 86: U.S. Market Share Analysis (%), By Test Type, 2022 & 2032
Figure 87: U.S. Market Share Analysis (%), By Indication, 2022 & 2032
Figure 88: U.S. Market Share Analysis (%), By End Users, 2022 & 2032
Figure 89: North America Vs. U.S. Growth Comparison
Figure 90: Canada Market Share Analysis (%), By Test Type, 2022 & 2032
Figure 91: Canada Market Share Analysis (%), By Indication, 2022 & 2032
Figure 92: Canada Market Share Analysis (%), By End Users, 2022 & 2032
Figure 93: North America Vs. Canada Growth Comparison
Figure 94: Brazil Market Share Analysis (%), By Test Type, 2022 & 2032
Figure 95: Brazil Market Share Analysis (%), By Indication, 2022 & 2032
Figure 96: Brazil Market Share Analysis (%), By End Users, 2022 & 2032
Figure 97: Latin America Vs. Brazil Growth Comparison
Figure 98: Mexico Market Share Analysis (%), By Test Type, 2022 & 2032
Figure 99: Mexico Market Share Analysis (%), By Indication, 2022 & 2032
Figure 100: Mexico Market Share Analysis (%), By End Users, 2022 & 2032
Figure 101: Latin America Vs. Mexico Growth Comparison
Figure 102: Argentina Market Share Analysis (%), By Test Type, 2022 & 2032
Figure 103: Argentina Market Share Analysis (%), By Indication, 2022 & 2032
Figure 104: Argentina Market Share Analysis (%), By End Users, 2022 & 2032
Figure 105: Latin America Vs. Argentina Growth Comparison
Figure 106: U.K. Market Share Analysis (%), By Test Type, 2022 & 2032
Figure 107: U.K. Market Share Analysis (%), By Indication, 2022 & 2032
Figure 108: U.K. Market Share Analysis (%), By End Users, 2022 & 2032
Figure 109: Europe Vs. U.K. Growth Comparison
Figure 110: Germany Market Share Analysis (%), By Test Type, 2022 & 2032
Figure 111: Germany Market Share Analysis (%), By Indication, 2022 & 2032
Figure 112: Germany Market Share Analysis (%), By End Users, 2022 & 2032
Figure 113: Europe Vs. Germany Growth Comparison
Figure 114: Italy Market Share Analysis (%), By Test Type, 2022 & 2032
Figure 115: Italy Market Share Analysis (%), By Indication, 2022 & 2032
Figure 116: Italy Market Share Analysis (%), By End Users, 2022 & 2032
Figure 117: Europe Vs. Italy Growth Comparison
Figure 118: France Market Share Analysis (%), By Test Type, 2022 & 2032
Figure 119: France Market Share Analysis (%), By Indication, 2022 & 2032
Figure 120: France Market Share Analysis (%), By End Users, 2022 & 2032
Figure 121: Europe Vs. France Growth Comparison
Figure 122: Spain Market Share Analysis (%), By Test Type, 2022 & 2032
Figure 123: Spain Market Share Analysis (%), By Indication, 2022 & 2032
Figure 124: Spain Market Share Analysis (%), By End Users, 2022 & 2032
Figure 125: Europe Vs. Spain Growth Comparison
Figure 126: Russia Market Share Analysis (%), By Test Type, 2022 & 2032
Figure 127: Russia Market Share Analysis (%), By Indication, 2022 & 2032
Figure 128: Russia Market Share Analysis (%), By End Users, 2022 & 2032
Figure 129: Europe Vs. Russia Growth Comparison
Figure 130: India Market Share Analysis (%), By Test Type, 2022 & 2032
Figure 131: India Market Share Analysis (%), By Indication, 2022 & 2032
Figure 132: India Market Share Analysis (%), By End Users, 2022 & 2032
Figure 133: South Asia Vs. India Growth Comparison
Figure 134: Thailand Market Share Analysis (%), By Test Type, 2022 & 2032
Figure 135: Thailand Market Share Analysis (%), By Indication, 2022 & 2032
Figure 136: Thailand Market Share Analysis (%), By End Users, 2022 & 2032
Figure 137: South Asia Vs. Thailand Growth Comparison
Figure 138: Malaysia Market Share Analysis (%), By Test Type, 2022 & 2032
Figure 139: Malaysia Market Share Analysis (%), By Indication, 2022 & 2032
Figure 140: Malaysia Market Share Analysis (%), By End Users, 2022 & 2032
Figure 141: South Asia Vs. Malaysia Growth Comparison
Figure 142: Indonesia Market Share Analysis (%), By Test Type, 2022 & 2032
Figure 143: Indonesia Market Share Analysis (%), By Indication, 2022 & 2032
Figure 144: Indonesia Market Share Analysis (%), By End Users, 2022 & 2032
Figure 145: South Asia Vs. Indonesia Growth Comparison
Figure 146: China Market Share Analysis (%), By Test Type, 2022 & 2032
Figure 147: China Market Share Analysis (%), By Indication, 2022 & 2032
Figure 148: China Market Share Analysis (%), By End Users, 2022 & 2032
Figure 149: East Asia Vs. China Growth Comparison
Figure 150: Japan Market Share Analysis (%), By Test Type, 2022 & 2032
Figure 151: Japan Market Share Analysis (%), By Indication, 2022 & 2032
Figure 152: Japan Market Share Analysis (%), By End Users, 2022 & 2032
Figure 153: East Asia Vs. Japan Growth Comparison
Figure 154: South Korea Market Share Analysis (%), By Test Type, 2022 & 2032
Figure 155: South Korea Market Share Analysis (%), By Indication, 2022 & 2032
Figure 156: South Korea Market Share Analysis (%), By End Users, 2022 & 2032
Figure 157: East Asia Vs. South Korea Growth Comparison
Figure 158: Australia Market Share Analysis (%), By Test Type, 2022 & 2032
Figure 159: Australia Market Share Analysis (%), By Indication, 2022 & 2032
Figure 160: Australia Market Share Analysis (%), By End Users, 2022 & 2032
Figure 161: Oceania Vs. Australia Growth Comparison
Figure 162: New Zealand Market Share Analysis (%), By Test Type, 2022 & 2032
Figure 163: New Zealand Market Share Analysis (%), By Indication, 2022 & 2032
Figure 164: New Zealand Market Share Analysis (%), By End Users, 2022 & 2032
Figure 165: Oceania Vs. New Zealand Growth Comparison
Figure 166: Turkey Market Share Analysis (%), By Test Type, 2022 & 2032
Figure 167: Turkey Market Share Analysis (%), By Indication, 2022 & 2032
Figure 168: Turkey Market Share Analysis (%), By End Users, 2022 & 2032
Figure 169: MEA Vs. Turkey Growth Comparison
Figure 170: GCC Market Share Analysis (%), By Test Type, 2022 & 2032
Figure 171: GCC Market Share Analysis (%), By Indication, 2022 & 2032
Figure 172: GCC Market Share Analysis (%), By End Users, 2022 & 2032
Figure 173: MEA Vs. GCC Growth Comparison
Figure 174: South Africa Market Share Analysis (%), By Test Type, 2022 & 2032
Figure 175: South Africa Market Share Analysis (%), By Indication, 2022 & 2032
Figure 176: South Africa Market Share Analysis (%), By End Users, 2022 & 2032
Figure 177: MEA vs. South Africa Growth Comparison
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
